Tracer library / [90Y]Y-hu5A10

[90Y]Y-hu5A10

Also written as [Y-90]hu5A10

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: Humanized monoclonal antibody (IgG1)
Target / mechanism: Targets free PSA (KLK3) PMID 33441295
Clinical application: Prostate cancer, including cases resistant to androgen receptor signaling inhibitor therapy PMID 33441295
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	—	—	hu5A10 DiaProst AB / Innovagen AB	33441295 2021 Clin Cancer Res The hu5A10 radio-immunoconstructs were prepared according to previously published protocols unique to the specific radionuclide (see supplementary methods).

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: DiaProst AB / Innovagen AB
Typical final purification: —

Need this precursor?We can point you to suppliers for [90Y]Y-hu5A10, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 33441295. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 33441295: 'Humanized 5A10 IgG1 mAb was developed by DiaProst AB (Lund, Sweden) and produced by Innovagen AB (Lund, Sweden)'. Stage set/updated at stage 23 from PMID 33441295: 'We present a complete preclinical evaluation of radiolabeled hu5A10 in mouse prostate cancer models and NHPs'.